CDTX: Gunggung utang perusahaan Cidara Therapeutics

Cidara Therapeutics (CDTX) operations are not subject to seasonality or market cycles, as they rely on medical testing phases. This chart reflects the current market value of individual debt, equal to 0.00, which accompanies the creation of advanced immune platforms to combat dangerous infections. The efficiency of preclinical stages is currently increasing due to the implementation of automated molecule screening systems in laboratories.

Cidara Therapeutics Inc - Utang perusahaan CDTX (periode 04.07.2022 - 17.01.2026)

Rincian analitis lan laporan data perusahaan Cidara Corp (CDTX)

- rega lan prakiraan konsensus rega:

Bagan owah-owahan rega Cidara Therapeutics Inc|CDTX - Prakiraan konsensus analis

- data kapitalisasi pasar:

Kapitalisasi pasar Cidara Therapeutics Corp|CDTX - Nilai Total Perusahaan

- data kapitalisasi buku:

Nilai Akuntansi Saham Cidara|CDTX - Nilai Buku Perusahaan|Rasio Kapitalisasi marang Aset Bersih cidara.com|CDTX - Total Aset Perusahaan

- data utang lan likuiditas:

Total Utang marang Modal Cidara Therapeutics|CDTX - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Cidara Therapeutics|CDTX - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Cidara Therapeutics Corp|CDTX - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Cidara

Analisis fundamental perusahaan:CDTX Cidara

This metric reflects the total volume of borrowed funds raised to support operational activities and growth. It allows for the separation of capital stability from market volatility, determining the fundamental margin of safety. By analyzing the total debt level on the GURU.Markets platform, an investor assesses the efficiency of leverage. For Cidara Therapeutics (CDTX), this metric is critical when financing costly joint developments of anti-infective drugs. An optimal balance of liabilities ensures the implementation of strategic alliances without the risk of insolvency.

Pesaing wigati

Kewajiban utang agregat Gilead Corp (GILD)|Gunggung utang perusahaan NVAX (Novavax, Inc.)|curevac.com - Gunggung utang perusahaan|Utang perusahaan Valneva (VALN)|VIR: Kewajiban utang agregat|SIGA (SIGA Corp) - Utang perusahaan|Emergent Bio (EBS) - Gunggung utang perusahaan|AVIR (Atea Pharmaceuticals) - Gunggung utang perusahaan|Gunggung utang perusahaan Invivyd Corp (IVVD)|Enanta Pharmaceuticals, Inc. (ENTA) - Gunggung utang perusahaan|Kewajiban utang agregat Inovio Pharmaceuticals, Inc. INO|Gunggung utang perusahaan HilleVax Corp HLVX|Utang perusahaan Kalaris Tx KLRS|Gunggung utang perusahaan DYAI (Dyadic)|NNVC: Gunggung kewajiban utang perusahaan|Utang perusahaan Talphera TLPH|Kewajiban utang agregat Cocrystal Pharma Inc|TRAW (Traws Pharma Inc) - Gunggung utang perusahaan|Gunggung utang perusahaan DWTX|QLGN (Qualigen Therapeutics) - Utang perusahaan|Gunggung kewajiban utang perusahaan allovir.com (ALVR)|VBI Vaccines - Gunggung utang perusahaan|Gunggung utang perusahaan Virios Therapeutics Inc. VIRI|Gunggung utang perusahaan VXRT (Vaxart Corp)